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AbstrACt
Introduction Most potential kidney transplant donors in 
the UK are aged over 60 years, yet increasing donor age is 
associated with poorer graft survival and function. Urgent 
preimplantation kidney biopsy can identify chronic injury, and 
may aid selection of better ‘quality’ kidneys from this group. 
However, the impact of biopsy on transplant numbers remains 
unproven. The PreImplantation Trial of Histopathology In renal 
Allografts (PITHIA) study will assess whether the introduction 
of a national, 24 hours, digital histopathology service increases 
the number, and improves outcomes, of kidneys transplanted 
in the UK from older deceased donors.
Methods and analysis PITHIA is an open, multicentre, 
stepped-wedge cluster randomised study, involving all UK 
adult kidney transplant centres. At 4-monthly intervals, a group 
of 4–5 randomly selected clusters (transplant centres) will be 
given access to remote, urgent, digital histopathology (total 
intervention period, 24 months). The trial has two primary end 
points: it is powered for an 11% increase in the proportion of 
primary kidney offers from deceased donors aged over 60 
years that are transplanted, and a 6 mL/min increase in the 
estimated glomerular filtration rate of recipients at 12 months 
post-transplant. This would equate to an additional 120 kidney 
transplants performed in the UK annually. Trial outcome data 
will be collected centrally via the UK Transplant Registry held 
by NHS Blood and Transplant (NHSBT) and will be analysed 
using mixed effects models allowing for clustering within 
centres and adjusting for secular trends. An accompanying 
economic evaluation will estimate the cost-effectiveness of the 
service to the National Health Service.
Ethics and dissemination The study has been given 
favourable ethical opinion by the Cambridge South Research 
Ethics Committee and is approved by the Health Research 
Authority. We will present our findings at key transplant 
meetings, publish results within 4 years of the trial 
commencing and support volunteers at renal patient groups to 
disseminate the trial outcome.
trial registration number ISRCTN11708741; Pre-results.
IntroduCtIon 
Kidney transplantation is the best treat-
ment for most patients with end-stage renal 
disease,1 2 but shortages in organs mean that 
patients in the UK wait around 3 years for a 
transplant.3 Over half of the potential pool 
of deceased donors (people dying in crit-
ical care) in the UK are older than 60 years.4 
Kidneys from donors aged over 60 years have 
been shown to carry a significantly higher risk 
of failure than those from younger donors,5 
and this failure is associated with a substan-
tially increased risk of recipient death.6 
Consequently, kidneys offered from donors 
of this age group are less frequently accepted, 
and once retrieved, are more commonly 
discarded.7 8 
need for a trial
One approach to assessing which kidneys 
from older deceased donors (aged >60 years) 
will provide acceptable long-term function is 
to perform a biopsy at organ retrieval. The 
strengths and limitations of this study
 ► Prospective, randomised evaluation of a clinical 
service using a novel stepped-wedge cluster design 
which avoids contamination of trial groups, while 
remaining acceptable to patients and study centres.
 ► The first national, 24 hours streamlined digital his-
topathology service, which will support all adult kid-
ney transplant centres in the UK and is likely to have 
applications beyond the trial setting.
 ► Example of a low cost ‘registry-based trial’ which 
uses routinely collected data and has a con-
comitant economic evaluation to determine 
cost-effectiveness.
 ► Use of two primary end points (and therefore nine 
possible trial outcomes) increases the possibility of 
an equivocal, rather than definitive result.
 ► To conserve power, the study will not be stopped 
early except on the grounds of patient safety.
 ► Thus, there is a risk that access to histopathol-
ogy may lead to fewer kidney transplants being 
performed.
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presence of chronic background injury is assessed histo-
logically and its severity can be scored using, for example, 
the Remuzzi grading system.9 Remuzzi has reported that 
this score correlates with subsequent transplant outcome, 
and has proposed that, depending on the score the kidney 
can either be transplanted singly (scores 1–3), discarded 
(scores≥6) or both kidneys from one donor transplanted 
into a single recipient (scores 4–5).9 One UK transplant 
centre (Cambridge) has established a preimplantation 
biopsy service using Remuzzi’s scoring system, but with 
a modified interpretation of the result. The Cambridge 
experience demonstrated that kidneys with scores of 
up to 4 are safe to be used individually, but those with 
scores of 5–6 should be transplanted together.10 Compar-
ison of Cambridge practice to UK transplant activity 
suggests that this approach resulted in greater numbers 
of kidney transplants being performed from older donors 
than would otherwise have been the case.7 Outcomes of 
the transplants were good, in that kidney graft survival 
from listing was similar to that achieved for all UK 
deceased kidney transplants—irrespective of donor 
age.11 However, Remuzzi’s approach has not been widely 
adopted across the UK. One major reservation, which this 
study will address, is whether biopsy-based selection leads 
to increased discard rates.12–14 In the USA, a large propor-
tion of kidneys are biopsied prior to implantation, and 
yet discard rates for kidneys from older donors are still 
high.15 In the expectation that preimplantation biopsy 
analysis is only useful in the subset of deceased donor 
kidneys in which chronic injury is prevalent, PreImplanta-
tion Trial of Histopathology In renal Allografts (PITHIA) 
will examine transplantation practice for kidneys from 
deceased UK donors aged over 60 years.
Trial implementation of a national histopathology 
service is not straightforward. A simple comparison of 
activity before and after the service is introduced would 
be unable to distinguish the impact of histopathology 
from the natural evolution in transplant practice over 
time. Alternatively, a trial in which individual kidneys 
are randomised with or without the option to biopsy is 
not practical. In that study, the availability of extra infor-
mation for only some kidneys would probably ‘contami-
nate’ (ie, change) acceptance practice of kidneys offered 
without it. The pool of elderly deceased kidney donors is 
already considered high-risk; therefore, implementation 
of that trial design would be likely to lead to an imme-
diate reduction in acceptance rates for those kidneys 
offered without a biopsy. The stepped-wedge design 
addresses these potential problems in two ways. First, the 
intervention is staggered over the duration of the trial 
with each centre acting as its own control. Second, at 
any given centre either all the kidneys will be available to 
biopsy, or none of them will. This should minimise intra-
centre contamination effects. Aside from ensuring that 
the study will have sufficient power to detect differences 
in the primary outcomes, the stepped-wedge design also 
has practical advantages over a standard parallel cluster 
evaluation.16 17 The stepped-wedge approach entails that 
the intervention is rolled out sequentially across the UK, 
which will allow the trial group time to provide a thor-
ough education programme at each participating centre. 
This programme will involve a discussion of the indica-
tions for, and subsequent interpretation of, the findings 
of an urgent kidney biopsy. Finally, the design ensures 
that all centres will eventually gain access to the biopsy 
service, and patient feedback was strongly in favour of a 
design which preserved the principle of equity of access.
study aims
This paper presents the protocol and rationale for an 
open, multicentre, stepped-wedge cluster, randomised, 
registry study. The study will introduce a new, national, 
histopathology service, and assess the impact of the 
service on transplant activity and outcomes. A concomi-
tant decision-model based economic evaluation will esti-
mate the lifetime cost-effectiveness of the service.
Specific aims of the study are to:
 ► Introduce a national histopathology service for 
transplantation that uses electronic image transfer 
to rationalise kidney biopsy processing to a limited 
number of designated biopsy centres.
 ► Perform a randomised evaluation of this service, by 
staggering its introduction to all the remaining UK 
renal transplant centres that do not currently have 
ready access to 24 hours renal histopathology. The 
evaluation will adhere to the principles of a stepped-
wedge cluster randomised study.
 ► Determine the cost-effectiveness of this service and 
thus make recommendations regarding whether it 
should be continued once the trial is completed, or 
not.
 ► Model a low cost randomised registry study that 
minimises costs because outcome data are collected 
centrally, which will shape future transplant research.18
 ► This protocol is reported in line with the Standard 
Protocol Items: Recommendations for Interventional 
Trials recommendations and has been adapted for 
publication from the original complete study protocol 
developed by the Trial Management Group (TMG).19
MEthods And AnAlysIs
description of study design
There will be 22 UK adult kidney transplant centres 
(each centre representing one cluster) participating in 
the randomisation. At 4-monthly intervals, a randomly 
selected group of four or five clusters will be given access 
to the new histopathology service. Access will enable 
clinicians to request preimplantation biopsy analysis as a 
means of evaluating the suitability of kidneys for trans-
plantation. The overall design is presented in figure 1. 
The study will compare the number of transplants 
performed, as well as the outcomes of these transplants 
before and after each centre gains access to urgent histo-
pathology. Every UK adult kidney transplant centre will 
participate over the 2 years. Cambridge is involved as one 
of the biopsy processing centres, although outcomes of 
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transplants performed will not be analysed. Cambridge 
already supports an urgent preimplantation biopsy 
service, and is therefore beyond clinical equipoise.
study hypotheses
This trial will test the hypothesis: ‘Provision of a national 
24/7 preimplantation biopsy service results, at reasonable 
cost, in transplantation of a greater proportion of kidneys 
offered from deceased donors aged ≥60 years, and/or 
improves kidney transplant function at 1-year post-trans-
plant. Numbers of deceased donor kidney transplants 
performed annually in the UK are consequently signifi-
cantly increased or improved in quality’.
Inclusion and exclusion criteria
A biopsy can be requested (at the time of offer) for 
organs which meet all the inclusion criteria and none 
of the exclusion criteria. The transplanting surgeon will 
always decide whether, or not, to biopsy an eligible organ. 
For the analysis, inclusion criteria are kidneys offered for 
transplantation from deceased donors (donation after 
circulatory (DCD) or brain stem (DBD) death) aged ≥60 
years. All kidneys offered as a component of a multiorgan 
transplant are excluded.
randomisation
We will use a restricted randomisation technique to 
randomly allocate the clusters to their cross-over date. To 
this end, we randomly will select a set of allocation sequences 
from 10 000 different allocations constrained so that the 
sum of the total cluster sizes observed under the interven-
tion condition is similar to the total sum of the cluster sizes 
in the control condition (using historic data). We define 
‘similar’ as a difference in the total sums (kidneys) exposed 
to intervention and control statuses being no different than 
expected middle 25th percentile range of differences. From 
this set, one allocation sequence will be selected at random.
Allocation will be performed by an independent stat-
istician once all site approvals are in place and will be 
revealed to the sites and the trial team approximately 
3 months before the date of transition. This approach 
enables a team of surgeons, renal nephrologists and 
renal histopathologists to provide a dedicated education 
package prior to those centres crossing over.
Intervention and control conditions
Control condition
UK renal transplant centres, with the exception of 
Cambridge, do not undertake urgent, preimplantation 
biopsy analysis. Therefore, the control condition is stan-
dard care, which involves accepting and transplanting 
kidneys from elderly deceased donors, based on donor 
clinical history and on macroscopic evaluation of the 
kidney on retrieval (figure 2). On trial commencement, 
acceptance and transplant activity of all centres will be 
monitored prior to their accessing the intervention, as 
this will establish baseline practice.
Figure 1 PreImplantation Trial of Histopathology In renal Allografts schema; stepped-wedge cluster randomised design.
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Intervention condition
Once a site has transitioned to the intervention condi-
tion they will have access to the national histopathology 
service (figure 2). Implanting surgeons at those transplant 
centres can then request a kidney biopsy at the time they 
are offered a kidney via the UK Transplant Registry held 
by NHS Blood and Transplant (NHSBT) Hub Operations. 
Requesting a biopsy is not mandatory—the transplant 
centres can use the service at their discretion. Transplant 
centres are also not obliged to adhere to a common set 
of guidelines governing biopsy use; they, along with their 
patients, retain the final say over whether a kidney should 
be biopsied, and/or transplanted.
Patients and their representatives have been involved 
in the design and implementation phases of PITHIA. 
Ahead of the trial starting, the TMG have met with key 
national kidney groups who have offered support for the 
trial by publicising it in their patient-facing publications. 
Each participating centre has also received a personalised 
information sheet to provide patients with an overview 
of the trial and the intended benefits. Final consent for 
any transplant will be obtained following a discussion of 
Figure 2 Logistics for biopsies in the control (2A) and intervention (2B) conditions. eGFR, estimated glomerular filtration rate.
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the potential risks and benefits of the individual kidney 
on offer, in line with standard practice and national 
guidelines.
biopsy method
A punch biopsy tool (5 mm diameter) will be used to take 
a sample from the upper pole of the kidney. Areas of the 
kidney which are scarred will be avoided. The 5 mm punch 
biopsy will be performed at the retrieval operation by the 
attending National Organ Retrieval Service (NORS) team 
and placed in formalin. The biopsy will be transported 
to the most appropriate histopathology centre, which 
will be determined on a case-by-case basis, with over-
sight from NHSBT Hub of Operations. Once the biopsy 
arrives at the processing centre, the on-call biomedical 
scientist will process the tissue and embed in wax then 
cut two sections and stain with H&E as well as Periodic 
Acid Schiff. They will then scan the slide using a 3DHIS-
TECH (Budapest, Hungary) Panoramic DESK scanner 
at high resolution (0.12 µm/pixel) and upload the files 
to a secure, centralised server managed by Sysmex UK 
(Milton Keynes, England).
At the time of protocol submission, there is one other 
national study using deceased-donor kidney biopsies 
(QUOD, http://www. quod. org. uk/ index. html). A single 
5 mm punch biopsy will provide enough material for 
both purposes and should be halved longitudinally, main-
taining full-depth cortical sampling in both pieces.
Primary outcome measures
1. Proportion of kidneys aged >60 years that are trans-
planted on first offer.
2. Estimated glomerular filtration rate (eGFR) measured 
at 12 months after transplant (acceptable range is be-
tween 10 and 15 months after transplant).20
secondary outcome measures
 ► Proportion of kidneys used overall (all formal offers 
for donors aged >60 years, not including fast-track 
offers).
 ► Total number of kidney transplants performed.
 ► Proportion of kidneys discarded after retrieval, out of 
all retrieved kidneys.
 ► Number and proportion of ‘single’ and ‘dual’ kidney 
transplants performed.
 ► Biopsy utilisation and fidelity, defined as the propor-
tion of kidneys that are biopsied in concordance with 
the education plan, out of all kidney biopsies.
 ► Kidney Donor Profile Index of transplants 
performed.21
 ► Cold ischaemia time, defined as the total time between 
perfusion of the donor kidneys with cold preservation 
fluid during retrieval, and reperfusion with recipient 
blood at implantation.
 ► 12-month patient survival.
 ► 12-month graft survival (censored for patient death).
 ► Proportion of kidneys diagnosed with primary 
non-function.
 ► Proportion of kidneys diagnosed with delayed graft 
function (defined as the use of dialysis during the first 
postoperative week).
Safety outcome measures
 ► Biopsy-related complication rate.
Subgroup analyses (the primary outcome will be repli-
cated for each subgroup):
 ► DBD donors only;
 ► DCD donors only;
 ► Donors who are aged >70 years;
 ► Centres with historically low median UK Kidney Donor 
Risk Index of transplanted DCD kidneys (low-risk 
transplants compared with overall UK activity).
The trial will use data that are routinely collected on 
the national UK Transplant Registry (UKTR), held by 
NHSBT. The national registry has a mandatory collec-
tion system that produces comprehensive information on 
organ donors, organs, transplants and recipients.
Trial closure
The trial will end 12 months after the final clusters have 
had access to the histopathology service for 4 months (36 
months after the start of the trial). This allows 12-month 
eGFR to be recorded for all kidneys which are eligible 
for inclusion in the analysis. The trial has no planned 
early stopping criteria, although the Trial Steering 
Committee have the power to stop the trial on safety 
grounds.
sample size calculations
Estimates for the sample size calculations were obtained 
from the UKTR, held by NHSBT. We followed the meth-
odology proposed by Hooper,22 23 and this was imple-
mented using SAS (V.9.4, Cary, North Carolina, USA) 
and the RShiny WebApp (https:// clusterrcts. shinyapps. 
io/ rshinyapp/).
First primary outcome: proportion of kidneys that are transplanted 
on first offer
Data were extracted on first kidney offers from potential 
deceased (DBD and DCD) donors aged 60 years and over, 
in the UK between 1 April 2014 and 31 March 2016. Offers 
of simultaneous pancreas kidney, multiorgan, fast-track and 
any offers to Cambridge were excluded. The percentage of 
first offers which were transplanted was 28.4%. The median 
number of first offers per cluster per month was 4.38. A 
mixed linear regression model was fitted to the extracted 
data, with a binary outcome (whether the offer resulted 
in a transplant), a fixed effect for date of offer (which was 
converted into year quarter, ie, six, 4-month time periods 
called period henceforth), a random effect for cluster and 
a random interaction between cluster and period. From this 
model, the within-period intracluster correlation (WP-ICC) 
and cluster autocorrelation (CAC) were calculated as 0.03 
and 0.92, respectively. Assuming an average cluster-period 
size of 18, to detect a 11% increase in the number of first 
offers transplanted, the trial will have 85% power (assuming 
a significance level of 2.5%) and would represent an increase 
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from 28% to 39% acceptance, which we believe would be 
considered clinically important. We have not allowed for 
attrition in this calculation as there is unlikely to be any 
missing data, due to the robustness of the offering data 
collected by NHSBT. We checked the sensitivity of this calcu-
lation by looking at an increase, and separately a decrease, 
of 2% in the baseline proportion, by varying the WP-ICC 
(lower WP-ICC set as 0 and upper WP-ICC set as 0.08) and 
the CAC (lower CAC set as 0.74 and upper CAC set as 1. The 
trial has within the region of 80% power for all anticipated 
values of WP-ICC and CAC, and likely values of cluster-pe-
riod sizes. The power curve, with the baseline proportion set 
as 28%, is shown in figure 3A.
Second primary outcome: eGFR measured at 12 months after 
transplant
Data were extracted on all recipients who received a 
kidney only transplant from deceased donors (DBD and 
DCD) aged ≥60 years, in the UK (excluding transplants 
at Cambridge) between 1 April 2014 and 31 March 2016. 
The median number of transplant recipients per cluster 
per month was 2, hence providing an average cluster-pe-
riod size of 8. eGFR was calculated using the 4-variable 
Modification of Diet in Renal Disease (MDRD) formula 
using uncalibrated serum creatinine measurements,20 
hence if missing data were present for the recipients sex, 
age, ethnicity and serum creatinine at 12 months, then 
eGFR could not be calculated (19%). The mean eGFR 
was 41.91 with an SD of 16.06.
A mixed linear regression model was fitted to this data, 
with a continuous outcome (eGFR), a fixed effect for date 
of transplant (which was converted into year quarter, ie, 
six, 4-month time periods), a random effect for cluster 
and a random interaction between cluster and period. 
From this model, the WP-ICC and CAC were calculated 
as 0.06 and 0.08, respectively. Assuming an average clus-
ter-period size of 8 (=2×4 clusters), this outcome will have 
89% power to detect a mean difference in eGFR of 6 mL/
min (assuming a significance level of 2.5%). We checked 
the sensitivity of this calculation by looking at an increase, 
and separately a decrease, of 0.5 in the mean difference; 
and by varying the WP-ICC by ±0.05 and CAC by ±0.016 
(which equates to ±20% of the base CAC). The trial has 
within the region of 80% power for all anticipated values 
of WP-ICC and CAC, and likely values of cluster-period 
sizes. The power curve, with the mean difference set as 6, 
is shown in figure 3B. As the CAC was particularly small, 
we separately explored the effects of a large CAC value 
(0.8) and found this had minimal impact.
Analysis plan
The primary outcome analyses will be performed 
according to the intention to treat. This will include all 
eligible patients for whom data have been obtained and 
will be analysed with respect to the treatment specified by 
the allocated randomisation order. The primary outcomes 
will be compared using two-sided tests and at a 2.5% signif-
icance level. Departures from randomisation at cluster 
level are defined as any cluster which does not switch to 
the intervention when stated in the randomisation order. 
A cluster is able to withdraw at any point during the trial. 
Per protocol analysis, which will exclude departures from 
randomisations and any cluster withdrawals, will also be 
completed for both primary outcomes of the trial. In situ-
ations where a pair of kidneys are transplanted as a ‘dual’ 
transplant into one recipient (eg, when the biopsy score 
is >4), this will be counted as half a transplant (in terms of 
utilisation, not as effective as performing two single trans-
plants, but better than discard).
Figure 3 (A) Power curve for the first primary outcome, proportion of kidneys that are transplanted on first offer. The curves 
show the increase in power as the cluster size increases, for 20 clusters, 5 steps, 4 clusters crossing over at each step and 
the proportion under control and intervention of 28% and 39%, respectively. The black curve shows the power for the base 
values of within-period intracluster correlation (WP-ICC) and cluster autocorrelation (CAC) (0.03 and 0.92, respectively), and the 
remaining curves show for lower and upper levels of the WP-ICC (0 and 0.08, respectively) and CAC (0.74 and 1, respectively). 
(B) Power curve for the second primary outcome estimated glomerular filtration rate measured at 12 months after transplant. 
The curves show the increase in power as the cluster size increases, for 20 clusters, 5 steps, 4 clusters crossing over at each 
step and the mean difference of 6 and SD of 16.06. The black curve shows the power for the base values of WP-ICC and 
CAC (0.06 and 0.08, respectively), and the remaining curves show for lower and upper levels of the WP-ICC (0.01 and 0.11, 
respectively) and CAC (0.06 and 0.10, respectively).
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Analysis of primary and secondary outcomes
All primary and secondary outcomes will adjust for 
calendar time, since the intervention is sequentially 
rolled out, and cluster, as participants within the same 
centre are not independent.
The primary aim of the study is to evaluate whether 
there is a difference in the use of kidneys from older 
donors before and after exposure to the intervention. For 
the first primary outcome, a logistic regression model, 
with random effects for cluster and cluster by period; and 
adjusting for period (fixed effect), will be used for the 
hypothesis test and to obtain the associated CI. This will 
be supplemented with a risk difference obtained from 
a binomial model with identity link, random effects for 
centre and centre by period; and adjusting for period 
(fixed effect). The absolute numbers will be presented 
by trial arm.
Mean eGFR values in each treatment group at 1 year 
will be compared using a normal regression model, 
adjusting for random cluster effect, random cluster by 
period interaction and a fixed effect for period. As eGFR 
at 12 months is only recorded for patients who are alive 
with a functioning graft at 12 months, the primary anal-
ysis will be complete case and there will be no imputation 
for missing values. The number of participants surviving 
to 12 months will be reported and of those the number 
who have a 12-month eGFR recorded. The adjusted mean 
and SD eGFR at 12 months will be reported by treatment 
arm, alongside the adjusted treatment difference with 
95% CI and p value.
A sensitivity analysis will repeat the analysis for the 
second primary outcome but with the following imputa-
tions: if a patient’s graft failed within 12 months, the eGFR 
at 12 months will be set to the mean value for patients on 
dialysis in the UK (currently 8.5 mL/min/1.73 m2).24 If a 
patient died with a functioning graft within 12 months 
of transplant, the 12-month eGFR will be set to the mean 
value at 12 months for all UK transplant patients with 
a functioning transplant at 1 year (currently 49.4 mL/
min/1.73 m2). This method assumes that deaths with a 
functioning graft will occur at random. Multiple impu-
tation was considered futile as insufficient clinical data 
are collected at the 12-month time point to accurately 
impute any missing measurements.
Other analyses
 ► Sensitivity analyses: although access to the urgent 
pathology service is immediate and preceded by 
formal education, it is still possible that the response 
(change in behaviour towards older donors) may be 
more gradual. To monitor this, a sensitivity analysis 
which excludes the first 2 weeks following crossover 
to the intervention arm will be conducted, to observe 
whether this significantly alters our conclusions.
 ► Variation of effect over time: an assessment of how 
all centres change their behaviour from the time 
they are introduced to the urgent biopsy service will 
be performed. This will be evaluated by estimating 
treatment effects by time since introduction of the 
intervention.
 ► Subgroups: the primary outcome will be replicated 
for each subgroup separately:
 – DBD donors only;
 – DCD donors only;
 – Donors who are aged >70 years;
 – Centres with a historic low median UK Kidney 
Donor Risk Index of transplanted DCD kidneys 
(low risk transplant activity).
Full details of the statistical analyses will be specified in 
the Statistical Analysis Plan.
Health economic analysis
A within-trial and decision model-based economic eval-
uation will be conducted from the perspective of the 
National Health Service (NHS), comparing the national 
histopathology service versus treatment as usual (no 
biopsy service). The within trial analysis will estimate the 
cost of the histopathology service including capital invest-
ment (eg, scanners), training for centres, staffing and 
transportation costs, and cost of patient NHS contacts (eg, 
dialysis, transplant surgery or secondary care contact). 
Cost data will be extracted from trial records and the 
UKTR, held by NHSBT. The outcome in the analysis will 
be the number of patients with a functioning transplant 
per centre standardised to a 12-month time horizon. The 
analysis will therefore report the incremental cost per 
incremental functioning kidney over 12 months.
The within-trial timeframe of 12 months is insufficient 
to fully capture the differences in costs and outcomes 
between the study arms. Therefore, a decision model-
based economic evaluation will predict demand and 
supply of kidneys for transplant in the UK, combining 
cost and outcomes evidence from the trial with other rele-
vant evidence from the literature to determine the incre-
mental cost per quality-adjusted life-year gained from the 
service. Full details of the economic analyses will be spec-
ified in the Health Economics Analysis Plan.
Patient and public involvement
Kidneys from donors aged over 60 years have been shown 
to carry a significantly higher risk of failure than those 
from younger donors. Transplant patients therefore face 
a dilemma at listing, ‘should I only accept kidneys from 
young healthy donors, but wait longer in doing so, or 
should I also accept kidneys from older, more marginal 
donors?’ Since 2014, Cambridge has discussed at listing, 
whether recipients are willing to accept kidneys from 
higher risk donors, including older donors. The central 
question of PITHIA—whether transplant rates from older 
donors can be increased with the use of preimplantation 
biopsy analysis—requires an underlying willingness from 
patients to accept these organs. In Cambridge, 75% (124 
of 169) of our listed population consented to kidneys 
from older donors, suggesting that this would also be 
accepted nationally among the wider transplant patient 
population.
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Success of the trial is critically dependent on ongoing 
patient involvement, because informed consent to receive 
an older kidney cannot be obtained without an appre-
ciation of the associated risks and how these are poten-
tially offset by biopsy analysis. During the design of the 
study, the trial group had lengthy discussions regarding 
key research questions, trial design and dissemination 
of results with patients. The proposed study design was 
presented at the National Kidney Advisory Group and 
Renal Transplant Services Meetings (which have patient 
and public involvement representation), with additional 
involvement of two of Cambridge renal transplant patients 
(one of whom is a co-applicant and sits on the steering 
group). These discussions shaped the development of 
the trial in several ways. In addressing the basic research 
question, patients felt that the particularly high rates of 
discard of kidneys from elderly DCD donors were diffi-
cult to justify. They also raised concerns relating to the 
inequity of access to transplantation between different 
UK renal transplant centres and felt strongly that the 
wide variation in waiting times for deceased donor trans-
plantation were unjustifiable.3 Their opinion was that 
this variation is at least partly due to differences in DCD 
kidney transplant practice and welcomed attempts (as 
in the current study) to improve transplant yields in this 
group. Patient concerns regarding inequity of access to 
kidney transplantation also had a major influence in 
trial design. We had originally proposed a conventional 
cluster randomised trial, in which half of the transplant 
centres were given access to the urgent biopsy service, 
and the other half continued as before, without access. 
However, the patients felt strongly that it was unfair to 
deprive some patients access to a service that may poten-
tially increase their chance of transplantation. As a result, 
we opted instead for a stepped-wedge cluster approach, 
because this way, the histopathology service is made avail-
able eventually to all centres.
Kidney patient groups have been extremely supportive 
of the trial and PITHIA has been publicised in multiple 
patient facing publications (including Kidney Life and 
Hope Kidney Patient’s Association). Additionally, the trial 
group continue to engage with the public through the 
study’s website ( www. pithia. org. uk), its twitter account (@
PITHIA_trial) and by publishing non-scientific summa-
ries in local media outlets (eg, Cambridge evening news, 
centre for evidence in transplantation, Cambridge NIHR 
biomedical research centre and Blood and Transplant 
matters).
dIsCussIon
This study will examine whether the introduction of a 
National Digital Pathology Service for urgent preim-
plantation kidney biopsy analysis increases the number 
of kidney transplants performed in the UK; or improves 
their outcomes. In doing so, the study will address the 
persisting controversy regarding the use of biopsies to 
decide which kidneys should be implanted singly, as part 
of a dual transplant or discarded.12–14 25 26 A successful 
study outcome—that kidney transplant numbers are 
increased, and the quality of grafts is maintained—would 
provide strong support that biopsy features correlate 
with long-term transplant function, and that the biopsy 
can be used as a predictive tool to inform transplanta-
tion decisions. However, there are several reasons why, 
despite a correlation with preimplantation biopsy anal-
ysis and transplant outcome, the trial may fail to show 
an increase in kidney transplant numbers. These include 
National Offering of a ‘marginal’ kidney from an elderly 
donor for a named recipient who is unsuitable for such a 
kidney—typically a very young recipient. In addition, the 
biopsy service will be introduced for use at the clinicians’ 
discretion, and either inappropriate biopsy use, or disre-
gard of biopsy findings may prejudice trial outcomes. 
Thus, to some extent, the trial tests the willingness of the 
UK kidney transplant body to adopt and observe biopsy 
practice.
Failure to provide biopsy results to clinicians promptly, 
reliably and safely all pose risks to service uptake after 
roll-out. The punch biopsy method was chosen because 
of its reliability, and to avoid the limitations of the more 
commonly used ‘needle core’ and ‘surgical wedge’ tech-
niques. The needle core is small, and it often contains 
insufficient numbers of glomeruli (25) and arteries 
(1) for Remuzzi assessment.27 28Second, the maximum 
depth of the needle is difficult to appreciate, particularly 
in a flaccid, non-perfused kidney. As a result, the core 
frequently samples medulla (not useful for analysis) and 
risks the deeper structures within the kidney. Alternatively, 
in performing the surgical wedge biopsy, the surgeon uses 
a scalpel to resect an ellipse of renal cortex. The quality 
of the sample is extremely variable, because there are no 
anatomical landmarks or standard measuring tools to 
guide the size or the depth of the sample. Additionally, 
when performing the ‘wedge’, there is generally a bias 
towards a superficial, subcapsular resection, which avoids 
damaging deeper structures but fails to sample the deep 
cortical tissue that is considered most representative of 
the ‘quality’ of the kidney graft. Wedge biopsies, partly 
because of their shape, tend to oversample the superfi-
cial cortex and overestimate the amount of glomerulo-
sclerosis because of the predominance of sclerosis in the 
subcapsular region.27 In contrast, the punch biopsy tool 
sets the dimensions of the sample, so it provides a consis-
tent, representative sample of renal cortex (equal volumes 
of superficial and deep cortex, more reliable sampling of 
arteries) without risking the deeper structures which are 
protected by the bevel which limits insertion to safe depth 
(8 mm).29 Once the sample is taken, it will immediately 
commence formalin fixation at the donor hospital, so 
that on arrival at the processing centre it should be ready 
for rapid processing (4 hours), thereby minimising any 
potential impact on the cold ischaemia time.
For the PITHIA study, a consortium of 15–20 volun-
tary consultant renal histopathologists from around the 
country will remotely assess and score the biopsies for 
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severity of chronic injury (by grading glomeruloscle-
rosis, tubular atrophy, interstitial fibrosis and arterial 
narrowing), and relay their assessment to the relevant 
transplant clinicians. The use of digital whole slide 
images avoids the need for the pathologist to be on-site 
to assess the glass slides, which requires an on-call rota at 
each centre—difficult to man with specialists. Thus, an 
important consequence of a national rota is the ability 
to efficiently provide a specialist on-call rota, with only 
one renal pathologist on-call for the whole country at any 
given time, with the option of a second backup pathol-
ogist to assist if busy or to provide a second opinion in 
difficult cases. Additionally, the trial group will provide 
training, feedback and discussion, allowing the patholo-
gists to converge on common thresholds of grading, mini-
mising interobserver variability. This will continue to be 
monitored during the trial.
PITHIA is an example of an effective, registry-based 
randomised trial, in which follow-up data are routinely 
collected as part of the mandatory post-transplant UKTR 
held by NHSBT. This has multiple advantages for the 
patients and the centres who are monitored following 
the intervention. Patients will avoid extra appointments, 
tests and the added bureaucracy generally associated 
with clinical trial participation. Similarly, once the trial 
has begun, transplant centres (other than those six 
centres providing the biopsy service) will have almost no 
extra work related to the trial. Compared with non-reg-
istry trials, data collection costs will be minimised, while 
participation is maximised.18 This saves substantially on 
trial costs.
EthICs And dIssEMInAtIon
This trial complies with the Declaration of Helsinki 
(2013). It will also be conducted in compliance with 
the approved protocol, the principles of Good Clinical 
Practice, the UK Data Protection Act, the requirements 
of the Human Tissues Act and the National Health 
Service Research Governance Framework for Health and 
Social Care. The trial has been prospectively registered 
with the ISRCTN (ISRCTN11708741).
We expect to present our findings to allied transplant 
professionals as oral presentations at key transplant 
meetings in the UK and abroad. We are also committed 
to publishing the results within 4 years of the trial 
commencing, in a journal compliant with Open Access. 
Any publication will coincide with local and national press 
release. If effective and cost-effective, we will consult with 
relevant NHS bodies to continue provision of the service. 
Volunteers from each of the renal patient groups attached 
to the various UK transplant centres will be supported in 
disseminating the trial results to the waiting list popula-
tion at each centre, and if proven effective and cost-effec-
tive, we hope to involve local kidney patient groups in the 
implementation of changes in local practice which follow 
on from this study.
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